Introduction
Current treatment options for infections caused by methicillinresistant Staphylococcus aureus (MRSA) are limited, but include vancomycin and newer agents such as linezolid and daptomycin. Ceftaroline has recently received FDA approval in the USA. 1, 2 This agent is a broad-spectrum cephalosporin with demonstrated in vitro activity against Gram-positive cocci, including MRSA, methicillin-resistant Staphylococcus epidermidis (MRSE), penicillin-resistant Streptococcus pneumoniae (PRSP) and vancomycin-resistant Enterococcus faecalis (not Enterococcus faecium). 1 -3 The broad-spectrum activity of ceftaroline includes most Gram-negative pathogens, but does not extend to extended-spectrum b-lactamase-producing Enterobacteriaceae or most non-fermentative Gram-negative bacilli. 1, 2 Ceftaroline fosamil (prodrug) is rapidly converted by plasma phosphatases to active ceftaroline. For multiple intravenous (iv) doses of 600 mg administered over 1 h every 12 h for 14 days, maximum plasma concentrations (C max ) were 19.0 and 21.0 mg/L for first and last doses, respectively. 1, 2 Ceftaroline has a volume of distribution of 0.37 L/kg (28.3 L), low protein binding (,20%) and a serum half-life of 2.6 h. 1, 2, 4 No drug accumulation occurs with multiple doses and elimination occurs primarily through renal excretion (49.6%). Dose adjustment is recommended for patients with moderate renal impairment (creatinine clearance 30 -50 mL/min) from 600 mg iv administered every 12 h to 400 mg iv administered every 12 h. 4 Ceftaroline has received FDA indications for complicated skin and skin structure infections (cSSSIs) including infections caused by MRSA and community-acquired pneumonia. The purpose of this study was to assess the pharmacodynamic activity of ceftaroline against community-and healthcareassociated MRSA, heteroresistant (h) vancomycin-intermediate S. aureus (hVISA), VISA and vancomycin-resistant S. aureus (VRSA) using an in vitro model.
Materials and methods

Bacterial strains and culture conditions
Ten S. aureus strains including two methicillin-susceptible S. aureus (MSSA), one community-associated (CA)-MRSA, one healthcareassociated (HA)-MRSA, one hVISA, three VISA and two VRSA were studied (see Table 1 ). The CA-MRSA and HA-MRSA were clinical strains obtained from the Canadian ward surveillance (CANWARD) study, a national surveillance study assessing antimicrobial resistance in Canadian hospitals. 5 The MRSA strains had the following genotypes: CA-MRSA 83771, CMRSA10/USA300P, Panton-Valentine leucocidin (PVL)+; and HA-MRSA 84495, CMRSA2/USA100/800, PVL2. 6 hVISA was assessed using the Etest macromethod. For the pharmacodynamic studies, logarithmic-phase cultures were prepared by initially suspending several colonies in cation-supplemented Mueller-Hinton broth (Oxoid, Nepean, Ontario, Canada) at a density equivalent to a 0.5 McFarland standard (1×10 8 cfu/mL). This suspension was then diluted 1:100 and 20 mL of the diluted suspension was further diluted in 60 mL of cation-supplemented Mueller-Hinton broth. Following overnight growth at 378C, suspensions were diluted 1:10 and 60 mL of the diluted suspension was added to the in vitro pharmacodynamic model. Viable bacterial counts consistently yielded a starting inoculum of approximately 1×10 6 cfu/mL.
9,10
Antibiotic preparations and susceptibility testing
Ceftaroline was obtained as laboratory-grade powder from the manufacturer (Forest Laboratories, Inc., New York, USA). Stock solutions were prepared and dilutions made according to the CLSI M7-A7 method.
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Following two subcultures from frozen stock, antimicrobial agent MICs for the strains were determined by the CLSI broth microdilution method. 11 All MICs were determined in triplicate on separate days.
Pharmacokinetics of ceftaroline in the in vitro pharmacodynamic model
Experiments were performed simulating peak free drug serum concentrations ( f C max ) and f AUC 24 of ceftaroline achieved in human serum after standard iv doses in healthy volunteers [ceftaroline dose 600 mg every 12 h ( f C max 16 mg/L)]. 1, 2, 12 Protein-free ( f ), also known as unbound serum concentrations were simulated using known protein binding fractions (ceftaroline 20% protein bound).
1,2,4 Ceftaroline clearance was simulated using a reported serum half-life of 2.6 h.
1,2 The pharmacokinetics of ceftaroline were evaluated by dosing using standard doses in the central compartment and sampling from this compartment at 0, 1, 2, 4, 6, 8, 12, 16 and 24 h. Ceftaroline concentrations were determined in quadruplicate using Escherichia coli ATCC 25922 as the test organism with a lower limit of quantification of 0.25 mg/L and were linear from 0.25 to 128 mg/L. 10 Specifically, concentrations were determined by measuring the diameters of zones of inhibition and comparing those zone sizes with zone sizes produced by known concentrations from a standard series. The lower and upper detection limits were 0.15 and 256 mg/L, respectively. Both the inter-day and intra-day variation was ,15%. The f AUC 24 (mg h/L) for ceftaroline was calculated using the trapezoidal rule. 9, 10 The f AUC 24 /MIC was calculated for ceftaroline against each of the S. aureus strains studied.
In vitro pharmacodynamic model/pharmacodynamic experiments
The in vitro pharmacodynamic model used in this study has been described previously. 9, 10 Logarithmic-phase cultures were diluted (1: 10) into fresh cation-supplemented Mueller -Hinton broth to achieve a starting inoculum of 1×10 6 cfu/mL. This initial inoculum was introduced into the central compartment (volume 610 mL) of the in vitro pharmacodynamic model and exposed to ceftaroline, simulating free (protein unbound) serum concentrations obtained after standard dosing at 600 mg every 12 h. All pharmacodynamic experiments were performed in ambient air at 378C and repeated in duplicate. At 0, 1, 2, 4, 6, 8, 12, 16 and 24 h, samples were removed from the central compartment and viable bacterial counts performed by plating serial 10-fold dilutions onto cation-supplemented Mueller-Hinton agar. Plates were incubated overnight at 378C in ambient air. The lowest dilution plated was 0.1 mL of undiluted sample and the lowest level of detection was 200 cfu/mL (20 colonies grown from 0.1 mL of undiluted sample). Antibiotic carryover was minimized by diluting samples withdrawn from the model. Cationsupplemented Mueller-Hinton agar plates containing ceftaroline concentrations of 0.5×, 1×, 2×, 4× and 8× MIC were used to assess the development of ceftaroline MIC increases at the 12 and 24 h sampling points.
Bacterial inhibition, including bactericidal (≥3 log 10 killing) activity and complete eradication of organisms from the model (below the limit of detection), was assessed at 6, 12 and 24 h. Ceftaroline bacterial growth inhibition at any timepoint was relative to the original inoculum ( 1×10 6 cfu/mL). Changes in cfu/mL at 6, 12 and 24 h (ceftarolinetreated organisms versus original inoculum) were compared using analysis of variance with Tukey's post hoc test. A P value ≤0.05 was considered significant.
Results
The ceftaroline and comparator susceptibility profiles of the 10 strains of S. aureus studied are presented in Table 1 . The two MSSA strains demonstrated ceftaroline MICs of 0.12 mg/L, while the three strains of MRSA (CA-MRSA, HA-MRSA and hVISA) produced ceftaroline MICs of 0.5 mg/L ( Table 1) . The VISA and VRSA strains demonstrated ceftaroline MICs of 0.5 or 1 mg/L (Table 1) . Vancomycin MICs for all MSSA and MRSA were 1 mg/L, while vancomycin MICs for strains of VISA and VRSA were 2 -4 mg/L and 64 mg/L, respectively (Table 1) .
Ceftaroline achieved pharmacokinetic values within 15% of the expected (simulated) pharmacokinetic values in the model. The achieved pharmacokinetic values of ceftaroline in the central compartment of the pharmacodynamic model were ceftaroline f C max 15+1.8 mg/L, t 1/2 2.7+0.5 h and f AUC 24 58.0+5.8 mg h/L. The achieved ceftaroline pharmacodynamic parameters were f T .MIC 92% -100%, f C max /MIC 16-133 and f AUC 24 /MIC 58 -483 (Table 2) .
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The pharmacodynamic activities of ceftaroline against MSSA, CA-MRSA, HA-MRSA, hVISA, VISA and VRSA are described in Table 3 . Against the two MSSA strains, ceftaroline f T .MIC ≥100% (ceftaroline MICs, 0.12 mg/L) resulted in bactericidal (≥3 log 10 killing) activity within 6 h after administration and completely eradicated the organisms from the model (below the limit of detection) at 24 h (Table 3) . With the CA-MRSA, HA-MRSA and hVISA strains, ceftaroline f T .MIC ≥100% (ceftaroline MICs 0.5 mg/L) resulted in bactericidal (≥3 log 10 killing) activity at 12 and 24 h after administration. No difference in bacterial killing was noted between CA-MRSA, HA-MRSA and hVISA strains (P .0.05). With the VISA and VRSA strains, ceftaroline f T .MIC ≥92% -100% (ceftaroline MICs, 0.5 -1 mg/L) resulted in bactericidal (≥3 log 10 killing) activity at 12 and 24 h after administration. Ceftaroline killing of a representative VISA strain is depicted in Figure 1 . No difference in bacterial killing for ceftaroline was observed between VISA, VRSA and MRSA strains (P .0.05). No bacterial regrowth occurred over the study period with any S. aureus studied and no changes in ceftaroline MICs were observed.
Discussion
We report that ceftaroline was bactericidal against MSSA, CA-MRSA, HA-MRSA, hVISA, VISA and VRSA. As CA-MRSA and VISA are emerging pathogens worldwide, new bactericidal therapies are needed.
1,2 Previous work has documented that the MIC 50 and MIC 90 of ceftaroline versus MRSA are 0.5 and 1 mg/L, respectively. 1 -3 This potent activity against MRSA includes CA-MRSA, HA-MRSA, VISA, VRSA and vancomycin-reduced susceptibility, daptomycin-non-susceptible and linezolid-non-susceptible S. aureus.
1 -3,13,14 Ceftaroline's MBC for these same strains is 1-to 2-fold higher than the MIC, demonstrating its bactericidal action. 13 The potent activity of ceftaroline versus MRSA is not Pharmacodynamics of ceftaroline versus MRSA, hVISA, VISA and VRSA surprising, given strong affinity (50% inhibitory concentration 0.01-19 mg/L, 256× that of ceftriaxone/cefotaxime) for penicillin binding protein 2a (PBP2a) in MRSA. 15, 16 Ceftaroline in time -kill studies has been reported to result in synergistic killing with tobramycin (at 0.5× MIC) against MRSA and this bacterial killing was greater than that for vancomycin in combination with tobramycin. 17 Using an in vitro pharmacodynamic model, Vidaillac et al. 18 showed that ceftaroline 600 mg every 12 h was superior in killing MRSA and hVISA compared with vancomycin 1 g every 12 h. Versus the hVISA strains studied, ceftaroline was not associated with ceftaroline MIC elevation on therapy, unlike vancomycin, which selected out vancomycin MIC elevations up to 8 -12 mg/L. 18 In our in vitro model we focused on the pharmacodynamic parameter f T .MIC for ceftaroline, simulating pharmacokinetics after typical doses used for cSSSIs. 1, 2, 4 Other investigators simulating ceftaroline pharmacodynamics in animals have reported that, as with other cephalosporins, f T .MIC is the pharmacodynamic parameter that is associated with bacterial killing. 3, 19 Using a rabbit endocarditis model, ceftaroline was shown to be both superior and bactericidal versus MRSA and VISA compared with vancomycin and linezolid. 20 In the same animal model, ceftaroline was reported to result in dose-dependent bacterial killing of MRSA, with 100% sterilization of aortic valve vegetations using the 40 mg/kg twice daily dose. 21 Ceftaroline's high rate of sterilization was greater than that of teicoplanin. 21 Using a rabbit model of acute MRSA and VISA osteomyelitis, ceftaroline was shown to be the most effective agent at reducing the inoculum of MRSA and VISA in joint fluid, bone marrow and bone compared with vancomycin and linezolid. 22 A summary of these in vitro and animal data shows that, unlike vancomycin, which is bacteriostatic against CA-MRSA, HA-MRSA, hVISA, VISA and VRSA, ceftaroline is bactericidal against these various S. aureus phenotypes. 11, 18, 21 Our previous work with vancomycin also showed that vancomycin was bacteriostatic against MSSA, MRSA and VISA, while demonstrating no activity versus VRSA. 10 Clinical reports comparing ceftaroline iv 600 mg every 12 h with vancomycin 1 g every 12 h with aztreonam in patients with cSSSIs have reported comparable microbiological and clinical efficacy. 23 -26 Clinical cure rates in patients with cSSSIs due to MRSA have shown that ceftaroline treatment results in comparable cure rates to vancomycin. 23 -26 These high clinical cure rates with ceftaroline are accompanied by the excellent safety of a cephalosporin with adverse effects including diarrhoea, nausea, headache and pruritis. 27 Limitations of the current study include the fact that we only dosed ceftaroline twice in our model and did not carry out experiments longer than 24 h. In the past, we have not documented significant differences in bacterial killing in 24 h experiments versus experiments lasting more than 24 h as long as multiple dosing has occurred. 1, 10 More importantly, as we could not obtain an S. aureus strain of any genotype with a ceftaroline MIC ≥2 mg/L, this precluded a full assessment of ceftaroline's pharmacodynamic activity against strains with elevated MICs. Currently, as reported by Jones et al., 3 few S. aureus strains with ceftaroline MICs of 4 mg/L (and none .4 mg/L) exist.
In conclusion, ceftaroline f T .MIC of ≥92% (ceftaroline MICs, ≤1 mg/L) was bactericidal (≥3 log 10 killing) against MSSA, CA-MRSA, HA-MRSA, hVISA, VISA and VRSA at 12 and 24 h.
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